Quick Answer
TScan Therapeutics, Inc. reported Operating Income Loss of -$135.81 million for the year ending 2025.
- TScan Therapeutics, Inc. showed a decrease of -0.7% in Operating Income Loss from 2024 to 2025.
- This data is from TScan Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$5.62 million | Q3 2020: -$7.17 million | Q1 2021: -$7.92 million | Q2 2021: -$10.68 million | Q3 2021: -$15.84 million | Q1 2022: -$16.16 million | Q2 2022: -$15.25 million | Q3 2022: -$16.58 million | Q1 2023: -$22.74 million | Q2 2023: -$24.61 million | Q3 2023: -$24.75 million | Q1 2024: -$31.37 million | Q2 2024: -$34.11 million | Q3 2024: -$32.62 million | Q1 2025: -$36.25 million | Q2 2025: -$38.65 million | Q3 2025: -$37.05 million.
- Over the full 6 years of available data (2020 to 2025), TScan Therapeutics, Inc.'s Operating Income Loss has declined by 417.7%.
- Historical annual values: Fiscal year 2025: -$135.81 million | Fiscal year 2024: -$134.82 million | Fiscal year 2023: -$93.46 million | Fiscal year 2022: -$66.64 million | Fiscal year 2021: -$48.64 million | Fiscal year 2020: -$26.23 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: